Novavax Inc. closed 64.88% below its 52-week high of $23.86, which the company reached on June 6th.

Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is ...

Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my post earnings update for NVAX stock.

Novavax (NVAX) announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his ...

Bullish option flow detected in Novavax (NVAX) with 10,455 calls trading, 2x expected, and implied vol increasing over 6 points to 78.51%. 3/14 ...

The stock's fall snapped a two-day winning streak.

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...